Wednesday, September 30, 2015 9:04:31 PM
If the CAFC rules for MNTA, there’s a pretty good chance of a settlement to the Lovenox patent case—and all outstanding litigation with AMPH—IMO
Let's hope so. I have been tempted to reinvest in MNTA, especially at recent prices, but the enoxaparin litigation still vexes me. It's tough for me to accept the possibility that the Federal Circuit could award Amphastar damages for the MNTA patented IP that it stole. I also have no sense of how long the MNTA/Sandoz generic Copaxone will retain its status as the sole generic. However, I do think that MNTA's other programs represent an enticing investment.
Eco Science Solutions Integrates IDScan.net's DIVE Into Herbo Pay to Power Identity Verification, Compliance, and Fraud Prevention • ESSI • Mar 27, 2026 12:01 PM
The Crypto Company Acquires FRAME Blockchain's Technology, An "Interstate Highway" Liquidity Layer for Crypto Commerce • CRCW • Mar 26, 2026 12:28 PM
Resilient Energy Inc. Enters LOI Negtiations for Second Acquisition; First Acquisition Nears Closing • RENI • Mar 26, 2026 10:30 AM
Alliance Creative Group (ACGX) Releases 2025 Annual Financial and Disclosure Report • ACGX • Mar 26, 2026 8:30 AM
Isiah Enterprises Activates Scalable Materials Platform Targeting $900B+ Global Market Opportunity; Initiates Strategic Partner Alignment Phase • OWPC • Mar 25, 2026 9:07 AM
ECGI Signs Definitive $25 Million Agreement to Acquire RezyFi • ECGI • Mar 24, 2026 8:30 AM
